A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...